You are about to leave the Clinical Value website now.


Utility of Combining PIVKA-II and AFP in the Surveillance and Monitoring of Hepatocellular Carcinoma in the Asia-Pacific Region

Quick Summary

A panel of 17 experts from the Asia-Pacific region reached a consensus on the clinical usefulness of protein-induced vitamin K absence II (PIVKA-II) for the surveillance and treatment monitoring of hepatocellular carcinoma (HCC). The experts agreed that PIVKA-II could be valuable in the detection of HCC in AFP-negative patients and for monitoring curative and intra-arterial locoregional treatments, outcomes, and recurrence. However, more evidence is required for the combined use of PIVKA-II with ultrasound and AFP for HCC surveillance, including small HCC. Implementing PIVKA-II in the region will also have challenges, such as standardizing cut-off values, cost-effectiveness, and improving awareness among healthcare providers.

You May Also Like

27 June 2024

Cost-Utility of Novel Biomarker-Based Strategies for Hepatocellular Carcinoma (HCC) Surveillance in Thailand

Read More
13 May 2024

No woman left behind: Increasing access to testing for cervical cancer elimination

Read More
13 May 2024

Advancing women’s health: Project Teal drives cervical cancer screening in Hong Kong

Read More


Be the first to receive updates, event opportunities, and thought leadership insights.